The Claim
Following discontinuation of tirzepatide, fat mass regain occurs preferentially in subcutaneous adipose depots (34%) compared to visceral adipose depots (7.5%), and the android-to-gynoid fat ratio decreases, indicating a shift toward a fat distribution pattern with lower metabolic risk.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
After stopping tirzepatide, fat that returns is more likely to accumulate under the skin than around internal organs, and the pattern of fat storage becomes less associated with metabolic disease.
See the scientific wording
After tirzepatide discontinuation, regained fat mass preferentially accumulates in subcutaneous depots (34%) rather than visceral depots (7.5%), and the android-to-gynoid fat ratio decreases, suggesting a shift toward a less metabolically harmful fat distribution.
After weight loss, the body stores returning fat mostly under the skin instead of around organs because fat cells under the skin become more efficient at taking up and holding fat, while fat cells around organs stay less active.
What the research says
1 studyStudy: 1676-P: Changes in Body Composition During and After Weight Loss with Tirzepatide
After people stopped taking tirzepatide, the fat that came back mostly stored under the skin instead of around the organs, which is a healthier way for fat to be stored.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.